移植肾慢性排斥时血清可溶性CD30表达的临床研究
|
摘要
近二十年来,随着新型免疫抑制剂的广泛使用和配型技术的不断改善,肾移植术后急性排斥反应已得到有效控制,但移植肾的长期存活率仍无明显提高,在全世界器官来源日益短缺的严峻形势下,如何使受者来之不易的移植物长期存活,成为移植工作者当前面临的一项重要课题和紧迫任务。
慢性排斥(chronic rejection,CR)是远期移植肾失功的主要原因。细胞免疫在移植肾各类排斥中的作用已经广为认可,2003年Terasaki重提器官移植体液免疫理论后,体液免疫在移植肾各类排斥中的作用也日益受到重视。目前,细胞免疫和体液免疫共同参与移植排斥的理论已经成为共识,Baff2005移植病理会议已经正式将抗体介导排斥反应的病理分类补充入Banff诊断标准中:即形态学上的组织损伤证据、补体4—d片段(completement 4d,C4d)在管周毛细血管(peritubular capillaries,PTC)的沉积、血清学检查供体特异性抗体(donor specificantibody,DSA)存在,结合临床表现,成为目前被广泛接受的移植肾排斥的诊断标准。
不论是细胞免疫还是体液免疫,它们都参与了移植肾慢性排斥反应是毫无疑问的。因此术后随访过程中通过某个免疫学指标对肾移植受者准确评价其免疫状态,对预测和早期诊断慢性排斥,评估抗排斥治疗的效果及指导免疫抑制剂应用都有重要意义。移植后免疫状态的检测方法较多,这些方法从不同的侧面检测受者体内的某些免疫指标,以期反映机体整个免疫系统的功能,截至目前,仍然缺乏全面理想的监测指标。采用临床肾功能生化指标、彩超等参数对移植肾功能的监测都是非特异性的,T淋巴细胞表型的检测(CD4/CD8)虽较好地反映了机体T淋巴细胞的免疫状态,但是对体液免疫因素却不能真实反映,群体反应性抗体(panel reactive antibody,PRA)为代表的抗HLA抗体的检测反映了抗体介导的体液免疫因素,应用广泛,但对大量PRA阴性患者,仍存在无法判断其免疫状态及移植排斥风险的局限,移植肾组织穿刺活检病理学检查加上免疫组化检测C4d对移植肾慢性排斥诊断具“金标准”价值,但是程序性穿刺活检对移植肾有创伤,病人多不愿接受。因此,寻找无创的诊断排斥的免疫学指标亦是目前移植免疫研究的重要内容。
Mosmann等于1986年根据产生的细胞因子及其生物学功能的不同,将鼠的辅助性T细胞(helper T cell,Th)分为Th1细胞和Th2细胞,Th1细胞通过分泌干扰素—γ(interferon-γ,IFN-γ)、白细胞介素2(Interleukin 2,IL-2)和肿瘤坏死因子-β(tumor necrosis factorβ,TNF-β)促进细胞免疫,Th2细胞通过分泌IL-4、IL-5、IL-6、IL-10、IL-13促进体液免疫。1991年Maggi等证实人的Th细胞同样划分为Th1细胞和Th2细胞,不同的是人Th1细胞和Th2细胞都可以产生IL-2;激活后的Th1细胞和Th2细胞分别表达不同的膜表面抗原,Th1细胞高表达淋巴细胞激活基因-3(LAG-3)及其编码蛋白,Th2细胞高表达CD30抗原,因此CD30抗原表达水平可反映Th2细胞的激活状态及其对免疫功能促进作用。
CD30是神经生长因子/肿瘤坏死因子受体超家族中的一员,是分子量为120KD的跨膜糖蛋白,其最先在何杰金病的Hodgkin和Reed Sternberg细胞表面上发现。CD30主要表达在分泌Th2型细胞因子的CD4~+T和CD8~+T细胞上,而在分泌Th1型细胞因子的T细胞上没有或仅低表达,其胞外部分能被蛋白酶切断而释放一个分子量为88,000的可溶形式CD30(soluble CD30,sCD30)。CD30通过与存在于B细胞膜上的CD30配体结合,再与CD30~+T细胞受体(Tcell receptor)发生交联,在IL-2存在的情况下发挥作用,一方面促进Th2细胞的分化和增殖,通过IL-2等调节细胞免疫,另一方面通过分泌IL-4、IL-5等促进体液免疫。CD30~+T淋巴细胞激活的免疫机制包含了体液免疫和细胞免疫,它的具体作用原理还需要大量的研究去阐明。CD30~+T淋巴细胞被激活后,sCD30会被释放入循环体液中,可被定量或定性检测到。
现有的研究已经证实,sCD30高水平表达与移植术后急性排斥发生和远期移植肾丢失风险增大有关。但是sCD30与远期移植肾慢性排斥反应的关系尚未有明确的报道。
本课题通过对慢性排斥患者的血清sCD30的检测,分析其在慢性排斥中异常表达的临床意义,并同时观察PRA、C4d体液免疫指标,比较它们在慢性排斥时表达的差异。
目的
通过研究血清sCD30在慢性排斥患者和移植肾功能正常受者中的表达,分析移植肾慢性排斥时临床检测血清sCD30的意义,比较其与PRA和C4d检测结果的差异。
方法
第一部分。病例来源于珠江医院,接受尸体肾移植一年以上,以Banff2005标准确定慢性排斥组(CR组)患者36例,采用单纯随机抽样方法抽取在我院行尸体肾移植,术后一年移植肾功能正常,门诊随访的106例移植肾功能稳定受者设为对照组,慢性排斥组每一病例留取血标本和活检标本时间相同即活检时间,对照组血标本则为门诊随机随访时间留取。首先用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)检测两组血清sCD30,回顾性分析CR组和对照组两组间sCD30表达的差异。
第二部分。移植肾穿刺活检36例CR组患者,免疫组化检测C4d,结合同时间点PRA、C4d指标,回顾性分析sCD30、PRA、C4d在慢性排斥中的表达差异。
所有数据均采用SPSS13.0统计软件分析。计量资料采用(均数±标准差),采用两独立样本t检验比较CR组和正常组的均数,两组计数资料的比较采用卡方检验。通过ROC曲线分析sCD30对于慢性排斥的诊断意义,术后PRA阳性与慢性排斥的关系进行危险度分析。P≤0.05为差异有统计学意义。
结果
1、血清sCD30的表达与慢性排斥
两组病人一般临床特征除性别有统计学差异(X~2=7.847,P=0.005),年龄、移植术前PRA、热缺血时间、冷缺血时间及术后免疫抑制剂方案方面,两组间比较均无统计学差异(P＞0.05)。
慢性排斥时,CR组和对照组血清sCD30和血肌酐水平分别是,CR组血清sCD30为(193.14±18.63)U/ml,血肌酐为(220.03±28.67)umol/L;对照组血清sCD30(65.45±19.12)U/ml,血肌酐为(104.41±30.35)umol/L。两组间血清sCD30和血肌酐比较有显著性差异(t=34.982,20.019;P=0.000,0.000)。ROC曲线分析显示灵敏度特异度趋向于100%和曲线下面积趋向为1时,血清sCD30值为135.50U/ml可为后续研究的参考临界值。
2、慢性排斥中sCD30表达与PRA、C4d指标关系
在CR组36例病人中,按术后PRA阴性、阳性为分类标准,血清sCD30在PRA阴性病人中为(191.13±19.11)U/ml(n=15),PRA阳性病人中为(194.57±18.62)U/ml(n=21),两者比较无显著性差异(t=0.540,P=0.593);同样CR组36例病人按C4d阴性、阳性分类,血清sCD30在C4d阴性病人中为(190.24±16.27)U/ml(n=17),C4d阳性病人中为(195.74±20.61)U/ml(n=19),两者比较也无显著性差异(t=0.515,P=0.608。在对照组106例受者中,同样按术后PRA阴性、阳性分类,术后PRA阳性受者血清sCD30为(67.32±20.63)U/ml(n=22),术后PRA阴性受者血清sCD30为(64.96±18.67)U/ml(n=84),两者进行统计学比较,同样无显著性差异(t=0.515,P=0.608)。
进一步分析36例CR组发现,PRA阳性21例(58.3%),C4d沉积阳性19例(52.8%),C4d阳性患者的术后PRA阳性率与C4d阴性患者的术后PRA阳性率相比,有显著性差异(84.2%vs29.4%,X~2=11.085,P=0.001)。
两组受者术后PRA与慢性排斥的危险度分析得知,术后PRA阳性与术后PRA阴性相比,发生慢性排斥的优势比为5.35,95%可信区间为(2.37,12.04),诊断慢性排斥的灵敏度和特异度分别为58.3%和79.2%,总的诊断准确率为73.9%(105/142)。
结论:
(1)血清sCD30异常升高与慢性排斥的发生密切相关,血清sCD30检测有助于对慢性排斥发生的诊断,本研究为sCD30作为一种无创的判断慢性排斥的免疫学指标提供了初步的临床参考数据。
(2)慢性排斥约半数有体液性免疫因素参加,PRA可较好地反映受体的体液免疫情况,但也存在PRA阴性时判断困难的情况,血清sCD30用于监测机体免疫状态较PRA全面,不受体液性因素影响,而与移植肾活检病理检查及C4d免疫组化染色相比,方法简单无创。
In recent 20 years,with the widely using of new kinds of immune suppressants and improving of HLA matching,acute rejection after renal transplantation have been well controlled,while long-term renal graft survival still have not been increased significantly.Under the grim situation of worldwide organs shorting,it is an importment study and an urgent task of transplatation workers to improve graft survival longer.
Chronic rejection is an important cause of late allograft dysfunction.Cell immunity has been recognized in all kinds of allograft rejections,in 2003, Pro.Terasaki emphasized the theory of humoral immunity again,the effect of humoral immunity on all kinds of allograft rejections has been thought highly increasingly.Nowadays,it is a common understanding that cell immunity and humoral immunity all play important roles in allograft rejections.Baff meetings of allograft pathology diagnostics has been replenished the antibody mediation rejection into the standards.
No matter cell immunity or hummoral immunity,it is no doubt that they all take part in chronic rejection.Therefore,it is vital for us to evaluate the recipients immunity state and diagnose the chronic rejection at early stage.Although there are many kinds methods to detect the recipients immunity state,these indexes all have their limitations to the whole recipients immunity system.For exemple,the detect of T lymph cell CD4/CD8 may reflect the recipients T lymph cell immunity state, but it can't tell us the information about humoral immunity.Another exemple is panel reactive antibody(PRA),it has been used to reflect the humoral immunity for many years and its clinical value has been admitted by us all,but for many many PRA negative recipients,it can not tell us the risk when the renal transplantations will be carried out.The allograft biopsy and pathological check including the C4d depsit in peritubular capillaries(PTC) is the gold standard for all kinds rejetion diagnostic,C4d is a degradation product of complement factor C4 during the classic complement pathway activated by antigen-antibody reaction and its doposit in renal graft tissure of peritubular capillaries is an established maker of humoral response in recipent,and the Banff schema has already admitted it as one of standards,but biopsy is an invasive method for recipients and allografts,so the recipients always don't accept this diagnostic method even if the allograft function has been damaged by unknown reasons.So,it is a very immportant and impending task for us to find some noninvasive and comprehansive indexes to lean about the recipients' immunity state.
Mosmann et al classified the mouse T-helper(Th) lymph cells into Th-1 type and Th-2 type according to the cytokines and its funtion in 1986,Th1 lymph cells can secret IFN-γ、IL-2和TNF-βand promote cell immunity,Th2 lymph cells can secret IL-4、IL-5、IL-6、IL-10、IL-13 and promote humoral immunity.In 1991, Maggi et al demonstrated that human Th lymph cells also classified into Th-1 type and Th2-type according to the cytokines and its funtion,and two kinds Th lymph cells could secrete IL-2.Th2 lymph cells has the membrane antigen CD30,and Thl lymph cells has no CD30.CD30 positive Th2 lymph cells can promote two kinds immunity reaction by secrete IL-2 and so on,so the CD30 level can comprehansive reflect the recipients immunity state.
The sCD30 molecule,a member of the tumor necrosis factor/nerve growth factor receptor superfamily was originally identifed as a cell surface antigen on Hodgkin's and Reed Sternberg cells and is preferentially expressed on human CD4+ and CD8+T cells that secrete Th2-type cytokines.No or low CD30 expression was found on Th1-type cytokine-secreting T cells.A soluble form of CD30(sCD30) is released into the bloodstream after activation of CD30+T cells.In diseases such as multiple sclerosis in which Th1-type immune responsese predominate,elevated sCD30 serum levels correlated with disease remission,In diseases in which Th2-type immune responses predominate,such as lupus erythematosus or atopic dermatitis, elevated serum sCD30 was associated with increased disease activity.Furthermore, increased serum sCD30 in the early stages of HIV infection predicted a rapid progress in acquired immunodeficiency syndrome.
In recent years,sCD30 has been studied that it is closely related to acute rejection and the outcomes of allografts,but there has no reports about the relationship between sCD30 and chronic rejection.
Based on CD30~+T cells immunity mechanism,which includes cell and humoral immunity,and there are many unknown specific principles that need us to study,our present study investigated whether increased serum levels of sCD30 could diagnose the chronic rejection in kidney allograft,and by contrasting the indexes of PRA、C4d,we wanted to demonstrate that sCD30 was a comprehansive useful and noninvasive index for chronic rejection diagnosis.
Objective:
To study the relationship between sCD30 and chronic rejection,and by contrasting the indexes of sCD30,PRA and C4d,we wanted to denmonstrate that sCD30 was a comprehansive useful and noninvasive index for chronic rejection diagnosis.
Methods:
The first part:all recipients were from the Zhujiang Hospital of the Southern Medical University,and the renal transplant operation had been passed over one year, according to Banff pathology diagnostic standards,36 recipients were chronic rejection group(CR),and 106 recipients who had normal allografts function were selected into the control group.The blood samples of chronic group were collected while the allografts were biopsied,and the blood samples of the control group were taken randomly when the recipients came to check at our outpatient. Firstly,we detected sCD30 by the means of ELISA,then retrospectively analyzed the difference of sCD30 levels between the CR group and the control group.The statistical method was“t”test between two separate samples,The difference was significant when P≤0.05.
The second part:36 cases in the CR group were all undergone allografts biopsy, and the allograft's tissue were detected C4d by immunohistochemisty method,and at the same time the PRA were tested again,we retrospectively analyzed the differences of sCD30 levels between the PRA or C4d positive group and negative group.The statistical method were“t”test and“x~2”test between two separate groups.The difference was significant when P≤0.05.
Results:
1.The relationship between serum sCD30 level and chronic rejection.
There were no significant differences in clinical features except gender between the CR group and the control group
There was significant difference in sCD30 levels between the CR group and the control group,the CR group sCD30 was(193.14±18.63) U/ml,the control group sCD30 was(65.45±19.12) U/ml,the statistic values were(t=34.982,P =0.000)。According to ROC curve analyse,serum sCD30 critical piont of statistical value is 135.50U/ml.
2.The relationship between serum sCD30,PRA and C4d.
Among the 36 cases in CR group,15 cases were PRA negative and 21 cases were PRA positive,there was no significant difference of sCD30 levels between PRA negative and PRA positive groups.Respectively,the sCD30 were PRA(-) (191.13±19.11) U/ml and PRA(+)(194.57±18.62) U/ml(t=0.540 P=0.593＞0.05).
Similarly,17 cases were C4d negative and19 cases were C4d positive among the 36 cases in CR group,there was no significant difference of sCD30 levels between the two groups.Respectively,the sCD30 were C4d(-)(190.24±16.27)U/ml and C4d(+)(195.74±20.61) U/ml,(t=0.515,P=0.608＞0.05).
The further analyse of CR group,PRA(+) ratio was 58.3%(21/36), C4d(+) ratio was 52.8%(19/36),between the PRA positive rate of C4d(+) and that ofC4d(-),there was significant difference(84.2%vs 29.4%,x~2=11.085,P= 0.001)。
According to the risk analyse between postopration PRA and chronic rejection in all 142 cases,compared the PRA positive cases to the PRA negtive cases, the optimistic ratio of chronic rejetion was 5.35,and the 95%confident interval was (2.37,12.04)。but the sensitivity and specificity of judgement on chronic rejection were only 58.3%and 79.2%,the total accurate rate is 73.9%(105/142)。
Conclusions:
(1)Abnormal elevated postoperation serum sCD30 is associated with chronic rejection,it is helpful for us to determine and predict the chronic rejetion that is happening.And our investigation may provide clinical data about sCD30 critical point.
(2)Compared to PRA,serum sCD30 is relatively comprehansive in detecting chronic rejection and we have not observed the humoral influence on it. And compared to allograft biopsy and C4d test,serum sCD30 detection is noninvasive importantly.
慢性排斥(chronic rejection,CR)是远期移植肾失功的主要原因。细胞免疫在移植肾各类排斥中的作用已经广为认可,2003年Terasaki重提器官移植体液免疫理论后,体液免疫在移植肾各类排斥中的作用也日益受到重视。目前,细胞免疫和体液免疫共同参与移植排斥的理论已经成为共识,Baff2005移植病理会议已经正式将抗体介导排斥反应的病理分类补充入Banff诊断标准中:即形态学上的组织损伤证据、补体4—d片段(completement 4d,C4d)在管周毛细血管(peritubular capillaries,PTC)的沉积、血清学检查供体特异性抗体(donor specificantibody,DSA)存在,结合临床表现,成为目前被广泛接受的移植肾排斥的诊断标准。
不论是细胞免疫还是体液免疫,它们都参与了移植肾慢性排斥反应是毫无疑问的。因此术后随访过程中通过某个免疫学指标对肾移植受者准确评价其免疫状态,对预测和早期诊断慢性排斥,评估抗排斥治疗的效果及指导免疫抑制剂应用都有重要意义。移植后免疫状态的检测方法较多,这些方法从不同的侧面检测受者体内的某些免疫指标,以期反映机体整个免疫系统的功能,截至目前,仍然缺乏全面理想的监测指标。采用临床肾功能生化指标、彩超等参数对移植肾功能的监测都是非特异性的,T淋巴细胞表型的检测(CD4/CD8)虽较好地反映了机体T淋巴细胞的免疫状态,但是对体液免疫因素却不能真实反映,群体反应性抗体(panel reactive antibody,PRA)为代表的抗HLA抗体的检测反映了抗体介导的体液免疫因素,应用广泛,但对大量PRA阴性患者,仍存在无法判断其免疫状态及移植排斥风险的局限,移植肾组织穿刺活检病理学检查加上免疫组化检测C4d对移植肾慢性排斥诊断具“金标准”价值,但是程序性穿刺活检对移植肾有创伤,病人多不愿接受。因此,寻找无创的诊断排斥的免疫学指标亦是目前移植免疫研究的重要内容。
Mosmann等于1986年根据产生的细胞因子及其生物学功能的不同,将鼠的辅助性T细胞(helper T cell,Th)分为Th1细胞和Th2细胞,Th1细胞通过分泌干扰素—γ(interferon-γ,IFN-γ)、白细胞介素2(Interleukin 2,IL-2)和肿瘤坏死因子-β(tumor necrosis factorβ,TNF-β)促进细胞免疫,Th2细胞通过分泌IL-4、IL-5、IL-6、IL-10、IL-13促进体液免疫。1991年Maggi等证实人的Th细胞同样划分为Th1细胞和Th2细胞,不同的是人Th1细胞和Th2细胞都可以产生IL-2;激活后的Th1细胞和Th2细胞分别表达不同的膜表面抗原,Th1细胞高表达淋巴细胞激活基因-3(LAG-3)及其编码蛋白,Th2细胞高表达CD30抗原,因此CD30抗原表达水平可反映Th2细胞的激活状态及其对免疫功能促进作用。
CD30是神经生长因子/肿瘤坏死因子受体超家族中的一员,是分子量为120KD的跨膜糖蛋白,其最先在何杰金病的Hodgkin和Reed Sternberg细胞表面上发现。CD30主要表达在分泌Th2型细胞因子的CD4~+T和CD8~+T细胞上,而在分泌Th1型细胞因子的T细胞上没有或仅低表达,其胞外部分能被蛋白酶切断而释放一个分子量为88,000的可溶形式CD30(soluble CD30,sCD30)。CD30通过与存在于B细胞膜上的CD30配体结合,再与CD30~+T细胞受体(Tcell receptor)发生交联,在IL-2存在的情况下发挥作用,一方面促进Th2细胞的分化和增殖,通过IL-2等调节细胞免疫,另一方面通过分泌IL-4、IL-5等促进体液免疫。CD30~+T淋巴细胞激活的免疫机制包含了体液免疫和细胞免疫,它的具体作用原理还需要大量的研究去阐明。CD30~+T淋巴细胞被激活后,sCD30会被释放入循环体液中,可被定量或定性检测到。
现有的研究已经证实,sCD30高水平表达与移植术后急性排斥发生和远期移植肾丢失风险增大有关。但是sCD30与远期移植肾慢性排斥反应的关系尚未有明确的报道。
本课题通过对慢性排斥患者的血清sCD30的检测,分析其在慢性排斥中异常表达的临床意义,并同时观察PRA、C4d体液免疫指标,比较它们在慢性排斥时表达的差异。
目的
通过研究血清sCD30在慢性排斥患者和移植肾功能正常受者中的表达,分析移植肾慢性排斥时临床检测血清sCD30的意义,比较其与PRA和C4d检测结果的差异。
方法
第一部分。病例来源于珠江医院,接受尸体肾移植一年以上,以Banff2005标准确定慢性排斥组(CR组)患者36例,采用单纯随机抽样方法抽取在我院行尸体肾移植,术后一年移植肾功能正常,门诊随访的106例移植肾功能稳定受者设为对照组,慢性排斥组每一病例留取血标本和活检标本时间相同即活检时间,对照组血标本则为门诊随机随访时间留取。首先用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)检测两组血清sCD30,回顾性分析CR组和对照组两组间sCD30表达的差异。
第二部分。移植肾穿刺活检36例CR组患者,免疫组化检测C4d,结合同时间点PRA、C4d指标,回顾性分析sCD30、PRA、C4d在慢性排斥中的表达差异。
所有数据均采用SPSS13.0统计软件分析。计量资料采用(均数±标准差),采用两独立样本t检验比较CR组和正常组的均数,两组计数资料的比较采用卡方检验。通过ROC曲线分析sCD30对于慢性排斥的诊断意义,术后PRA阳性与慢性排斥的关系进行危险度分析。P≤0.05为差异有统计学意义。
结果
1、血清sCD30的表达与慢性排斥
两组病人一般临床特征除性别有统计学差异(X~2=7.847,P=0.005),年龄、移植术前PRA、热缺血时间、冷缺血时间及术后免疫抑制剂方案方面,两组间比较均无统计学差异(P＞0.05)。
慢性排斥时,CR组和对照组血清sCD30和血肌酐水平分别是,CR组血清sCD30为(193.14±18.63)U/ml,血肌酐为(220.03±28.67)umol/L;对照组血清sCD30(65.45±19.12)U/ml,血肌酐为(104.41±30.35)umol/L。两组间血清sCD30和血肌酐比较有显著性差异(t=34.982,20.019;P=0.000,0.000)。ROC曲线分析显示灵敏度特异度趋向于100%和曲线下面积趋向为1时,血清sCD30值为135.50U/ml可为后续研究的参考临界值。
2、慢性排斥中sCD30表达与PRA、C4d指标关系
在CR组36例病人中,按术后PRA阴性、阳性为分类标准,血清sCD30在PRA阴性病人中为(191.13±19.11)U/ml(n=15),PRA阳性病人中为(194.57±18.62)U/ml(n=21),两者比较无显著性差异(t=0.540,P=0.593);同样CR组36例病人按C4d阴性、阳性分类,血清sCD30在C4d阴性病人中为(190.24±16.27)U/ml(n=17),C4d阳性病人中为(195.74±20.61)U/ml(n=19),两者比较也无显著性差异(t=0.515,P=0.608。在对照组106例受者中,同样按术后PRA阴性、阳性分类,术后PRA阳性受者血清sCD30为(67.32±20.63)U/ml(n=22),术后PRA阴性受者血清sCD30为(64.96±18.67)U/ml(n=84),两者进行统计学比较,同样无显著性差异(t=0.515,P=0.608)。
进一步分析36例CR组发现,PRA阳性21例(58.3%),C4d沉积阳性19例(52.8%),C4d阳性患者的术后PRA阳性率与C4d阴性患者的术后PRA阳性率相比,有显著性差异(84.2%vs29.4%,X~2=11.085,P=0.001)。
两组受者术后PRA与慢性排斥的危险度分析得知,术后PRA阳性与术后PRA阴性相比,发生慢性排斥的优势比为5.35,95%可信区间为(2.37,12.04),诊断慢性排斥的灵敏度和特异度分别为58.3%和79.2%,总的诊断准确率为73.9%(105/142)。
结论:
(1)血清sCD30异常升高与慢性排斥的发生密切相关,血清sCD30检测有助于对慢性排斥发生的诊断,本研究为sCD30作为一种无创的判断慢性排斥的免疫学指标提供了初步的临床参考数据。
(2)慢性排斥约半数有体液性免疫因素参加,PRA可较好地反映受体的体液免疫情况,但也存在PRA阴性时判断困难的情况,血清sCD30用于监测机体免疫状态较PRA全面,不受体液性因素影响,而与移植肾活检病理检查及C4d免疫组化染色相比,方法简单无创。
In recent 20 years,with the widely using of new kinds of immune suppressants and improving of HLA matching,acute rejection after renal transplantation have been well controlled,while long-term renal graft survival still have not been increased significantly.Under the grim situation of worldwide organs shorting,it is an importment study and an urgent task of transplatation workers to improve graft survival longer.
Chronic rejection is an important cause of late allograft dysfunction.Cell immunity has been recognized in all kinds of allograft rejections,in 2003, Pro.Terasaki emphasized the theory of humoral immunity again,the effect of humoral immunity on all kinds of allograft rejections has been thought highly increasingly.Nowadays,it is a common understanding that cell immunity and humoral immunity all play important roles in allograft rejections.Baff meetings of allograft pathology diagnostics has been replenished the antibody mediation rejection into the standards.
No matter cell immunity or hummoral immunity,it is no doubt that they all take part in chronic rejection.Therefore,it is vital for us to evaluate the recipients immunity state and diagnose the chronic rejection at early stage.Although there are many kinds methods to detect the recipients immunity state,these indexes all have their limitations to the whole recipients immunity system.For exemple,the detect of T lymph cell CD4/CD8 may reflect the recipients T lymph cell immunity state, but it can't tell us the information about humoral immunity.Another exemple is panel reactive antibody(PRA),it has been used to reflect the humoral immunity for many years and its clinical value has been admitted by us all,but for many many PRA negative recipients,it can not tell us the risk when the renal transplantations will be carried out.The allograft biopsy and pathological check including the C4d depsit in peritubular capillaries(PTC) is the gold standard for all kinds rejetion diagnostic,C4d is a degradation product of complement factor C4 during the classic complement pathway activated by antigen-antibody reaction and its doposit in renal graft tissure of peritubular capillaries is an established maker of humoral response in recipent,and the Banff schema has already admitted it as one of standards,but biopsy is an invasive method for recipients and allografts,so the recipients always don't accept this diagnostic method even if the allograft function has been damaged by unknown reasons.So,it is a very immportant and impending task for us to find some noninvasive and comprehansive indexes to lean about the recipients' immunity state.
Mosmann et al classified the mouse T-helper(Th) lymph cells into Th-1 type and Th-2 type according to the cytokines and its funtion in 1986,Th1 lymph cells can secret IFN-γ、IL-2和TNF-βand promote cell immunity,Th2 lymph cells can secret IL-4、IL-5、IL-6、IL-10、IL-13 and promote humoral immunity.In 1991, Maggi et al demonstrated that human Th lymph cells also classified into Th-1 type and Th2-type according to the cytokines and its funtion,and two kinds Th lymph cells could secrete IL-2.Th2 lymph cells has the membrane antigen CD30,and Thl lymph cells has no CD30.CD30 positive Th2 lymph cells can promote two kinds immunity reaction by secrete IL-2 and so on,so the CD30 level can comprehansive reflect the recipients immunity state.
The sCD30 molecule,a member of the tumor necrosis factor/nerve growth factor receptor superfamily was originally identifed as a cell surface antigen on Hodgkin's and Reed Sternberg cells and is preferentially expressed on human CD4+ and CD8+T cells that secrete Th2-type cytokines.No or low CD30 expression was found on Th1-type cytokine-secreting T cells.A soluble form of CD30(sCD30) is released into the bloodstream after activation of CD30+T cells.In diseases such as multiple sclerosis in which Th1-type immune responsese predominate,elevated sCD30 serum levels correlated with disease remission,In diseases in which Th2-type immune responses predominate,such as lupus erythematosus or atopic dermatitis, elevated serum sCD30 was associated with increased disease activity.Furthermore, increased serum sCD30 in the early stages of HIV infection predicted a rapid progress in acquired immunodeficiency syndrome.
In recent years,sCD30 has been studied that it is closely related to acute rejection and the outcomes of allografts,but there has no reports about the relationship between sCD30 and chronic rejection.
Based on CD30~+T cells immunity mechanism,which includes cell and humoral immunity,and there are many unknown specific principles that need us to study,our present study investigated whether increased serum levels of sCD30 could diagnose the chronic rejection in kidney allograft,and by contrasting the indexes of PRA、C4d,we wanted to demonstrate that sCD30 was a comprehansive useful and noninvasive index for chronic rejection diagnosis.
Objective:
To study the relationship between sCD30 and chronic rejection,and by contrasting the indexes of sCD30,PRA and C4d,we wanted to denmonstrate that sCD30 was a comprehansive useful and noninvasive index for chronic rejection diagnosis.
Methods:
The first part:all recipients were from the Zhujiang Hospital of the Southern Medical University,and the renal transplant operation had been passed over one year, according to Banff pathology diagnostic standards,36 recipients were chronic rejection group(CR),and 106 recipients who had normal allografts function were selected into the control group.The blood samples of chronic group were collected while the allografts were biopsied,and the blood samples of the control group were taken randomly when the recipients came to check at our outpatient. Firstly,we detected sCD30 by the means of ELISA,then retrospectively analyzed the difference of sCD30 levels between the CR group and the control group.The statistical method was“t”test between two separate samples,The difference was significant when P≤0.05.
The second part:36 cases in the CR group were all undergone allografts biopsy, and the allograft's tissue were detected C4d by immunohistochemisty method,and at the same time the PRA were tested again,we retrospectively analyzed the differences of sCD30 levels between the PRA or C4d positive group and negative group.The statistical method were“t”test and“x~2”test between two separate groups.The difference was significant when P≤0.05.
Results:
1.The relationship between serum sCD30 level and chronic rejection.
There were no significant differences in clinical features except gender between the CR group and the control group
There was significant difference in sCD30 levels between the CR group and the control group,the CR group sCD30 was(193.14±18.63) U/ml,the control group sCD30 was(65.45±19.12) U/ml,the statistic values were(t=34.982,P =0.000)。According to ROC curve analyse,serum sCD30 critical piont of statistical value is 135.50U/ml.
2.The relationship between serum sCD30,PRA and C4d.
Among the 36 cases in CR group,15 cases were PRA negative and 21 cases were PRA positive,there was no significant difference of sCD30 levels between PRA negative and PRA positive groups.Respectively,the sCD30 were PRA(-) (191.13±19.11) U/ml and PRA(+)(194.57±18.62) U/ml(t=0.540 P=0.593＞0.05).
Similarly,17 cases were C4d negative and19 cases were C4d positive among the 36 cases in CR group,there was no significant difference of sCD30 levels between the two groups.Respectively,the sCD30 were C4d(-)(190.24±16.27)U/ml and C4d(+)(195.74±20.61) U/ml,(t=0.515,P=0.608＞0.05).
The further analyse of CR group,PRA(+) ratio was 58.3%(21/36), C4d(+) ratio was 52.8%(19/36),between the PRA positive rate of C4d(+) and that ofC4d(-),there was significant difference(84.2%vs 29.4%,x~2=11.085,P= 0.001)。
According to the risk analyse between postopration PRA and chronic rejection in all 142 cases,compared the PRA positive cases to the PRA negtive cases, the optimistic ratio of chronic rejetion was 5.35,and the 95%confident interval was (2.37,12.04)。but the sensitivity and specificity of judgement on chronic rejection were only 58.3%and 79.2%,the total accurate rate is 73.9%(105/142)。
Conclusions:
(1)Abnormal elevated postoperation serum sCD30 is associated with chronic rejection,it is helpful for us to determine and predict the chronic rejetion that is happening.And our investigation may provide clinical data about sCD30 critical point.
(2)Compared to PRA,serum sCD30 is relatively comprehansive in detecting chronic rejection and we have not observed the humoral influence on it. And compared to allograft biopsy and C4d test,serum sCD30 detection is noninvasive importantly.
引文
[1]Solez K,Colvin RB,Racusen LC,et al.Banff'2005 Meeting Report:different diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy.Am J Transplant,2007,7:518-526.
[2]文吉秋,季曙明.慢性移植肾功能不全的原因与防治.肾脏病与透析肾移植杂志[J].2005,14:568-573.
[3]Terasaki PI.Humoral theory of transplantation.Am J Transplant,2003,3:665-673.
[4]Cai J,Terasaki PI.Humoral theory of transplantation:mechanism,prevention,and treatment.Hum Immunol.2005,66:334-342.
[5]Sureshumar KK,Hussain SM,Carpenter BJ,et al.Antibody-mediated rejection follwoong renal transplantation.Expert Opin Pharmacother,2007,8:913-921.
[6]Regele H,Exner M,Watschinger B,et al.Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection.Nephrol Dial Transplant,2001,16(10):2058-2066.
[7]Regele H,Bohmig GA,Haicht A,et al.Capillary deosition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries:A contribution of humoral immunity to chronic allograft rejection.J Am Soc Nephrol,2002,13(9):2371-2380.
[8]Collins AB,Schneeberger EE,Pascual MA,et al.Complemen activation in acute humoral renal allograft rejection:diagnostic significance of C4d deposits in peritubular capillaries.J Am Soc Nephrol,1999,10(10):2208-2214.
[9]Mosmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell.J Immunol,1986,136(7):2348-2357.[]
[10]Maggie E,Biswar R,Pnete GD,et al.Accumulation of Th2 like helper T cells in the conjunctiva of patients with vernal conjunctivitis.J Immunol,1991,146:1169-1174.
[11]Durkop H,Latza U.Molecular cloning and expression of a new member of the nerve groth factor receptor family that is characteristic for Hodgkin's disease.Cell, 1992,68:421-427.
[12]Del Prete G et al.Preferential expression of CD30 by human CD4+T cells producing Th2-type cytokines.FASEB J,1995,9:81.
[13]Romagnani S,Del Prete G,et al.CD30 and type 2 T-helper(Th2)responses.J Leukoc Biol,1995,57:726-730.
[14]Rebhandl W,Felberbauer FX,Rwsch S,et al.Value of circulating immune parameters in renal transplantation.Transplant Proc,1997,29:1881.
[15]SUSAL C,PELZL S,SIMON T,et al.Advances in pre- and post-transplant immunologic testing in kidney transplantation[J].Transplantation Proc,2004,36:29-34.
[16]SUSAL C,PELZL S,DOHLER B,et al.Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30[J].J Am Soc Neprol,2002,13:1650-1656.
[17]McMillan SA,McDonnell GV,et al.Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis.Neurology,1998,51:1156-1160.
[18]PELZL S,OPELZ G,DANNIEL V,et al.Evaluation of post-transplantati on soluble CD30 for diagnosis of acute renal allograft rejection[J].Transplantation,2003,75:421-423.
[19]PELZL S,OPELZ G,WIESEL M,et al.Soluble CD30 as a predictor of kidney allograft outcome[J].Transplantation ,2002,73:3-6.
[20]SUSAL C,PELZL S,OPELZ G.Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.Transplantation,2003,76:1231-1232.
[21 ]Barth S,Huhn M.Ki-4(scFv)-ETA,a new recombinant anti-CD30 immunotoxin Nscid mice.Blood,2000,95:3909-3914.
[22]Gebel HM,Bray RA,Nickerson P.Pre-transplant assessment of donor-reactive,HLA-specific antibodies in renal transplantation:contraindication vs.risk.Am J Transplant,2003,3( 12):1488-1500.
[23]Kennedy MK,Willis CR,Armitage RJ.Deciphering CD30 ligand biologyand its role in humoral immunity.Immunology,2006,118(2):143-152.
[1]Montgomery RA,Hardy MA,Jordan,SC,et al.Consensus opinion from the antibody working group on the diagnosis,reporting,and risk assessment for antibody-mediated rejection and desensitization protocols.Transplantation,2004,78:181_185.
[2]Terasaki PI.Humoral theory of transplantation.Am J Transplant,2003,3:665-673.
[3]Racusen LC,Colvin RB,Solez K,et al.Antibody-mediated rejection criteria an addition to Banff 97 classification of renal allograft rejection.Am J Transplant,2003,3:708-714.
[4]Colvin RB,Smith RN.Antibody mediated organ allograft rejection.Nature Rev.Immunol,2005,5:807-817.
[5]Sumitran-Holgersson S,Wilczek HE,Holgersson J,et al.Identification of the nonclassical HLA molecules MICA,as targets for humoral immunity associated with irreversible rejection of kidney allografts.Transplantation,2002,74:268-277.
[6]Dragun D,M ller DN,B r sen JH,et al.Angiotensin Ⅱ type-receptor-activiating antibodies in renal-allograft rejection.N Engl J Med,2005,352:558-569.
[7]Sun Qiquan,Liu Zhihong,Yin Guang,et al.Detectable circulating antiendothelial cell antibodies in renal-allograft recipient with C4d positive acute rejection:a report of three cases.Transplantation,2005,79:1759-1762.
[8]谭建明,周永昌,唐孝达,主编.组织配型技术与临床应用.第1版.人民卫生出版社,2002.
[9]Desvaux D,Le-Gouvello S,Pastural M,et al.Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates:high gamma-interferon expressoin andpoor clinical outcome.Nephrol Dial Transplant,2004,19:933-939.
[10]Baldwin WM,Kasper EK,Zachary AA,et al.Beyond C4d:other complement-related diagnositic approaches to antibody-mediated rejection.Am J Transplant,2004,4:311-318.
[11]Sacks SH,Chowdhury P,Zhou W.Role of the complement system in rejection.Curr Oppin Immunol,2003,15:487-492.
[12]Lepin EJ,Reed EF.Complement-independent mechanisms of antigraft antibodies in transplant arteriosclerosis and accommodation.Curr Opin Organ Transplant,2004,9:10-15.
[13]Mauiyyedi S,Crespo M,Collins AB,et al.Acute humoral rejection in kidney tranplanttation:Ⅱ Morphology,immuno-pathology,and pathologic classification.J Am Soc Nephrol,2002,13:779-787.
[14]Takemoto SK,Zeevl A,Feng S,et al.National conference to assess antibody-mediated rejection in solid organ transplantation.Am J Transplant,2004,12:2482-2489.
[15]Bohmig GA,Regele H,Exner M,et al.C4d-positive acute humoral renal allograft rejection:effective treatment by immunoadsortion.J Am Soc Nephrol,2001,12:2482-2489.
[16]Pascual M,Saidman S,Tolkoff-Rubin N,et al.Plasma exchange and tarcrolimus-mycophenolate rescue for acute humoral rejection.Curr Oppin ogan Transplant,2004,9:29-35.
[17]Montgomery RA,Zachary AA,Racusen LC,et al.Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch positive recipients.Transplantation,2000,70:889-895.
[18]Rocha PN,Butterly DW,Greenberg A,et al.Beneficial effects of plasmapheresis and intravenous immune globulin on renal allograft survival of patients with acute humoral rejection.Transplantation,2003,75:1490-1495.
[19]Jordan SC,Vo A,Bunnap radist S,et al.Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.Transplantation,76:631-636.
[20]Frank MM,Miletic VD,Jiang H.Immunoglobulin in the control of complement action.Immunol Res,2000,22:137-146.
[1]Schwab U,Stein H,Gerdes J,Lemke H,Kirchner H,Schaadt M,et al.Production of a monoclonal antibody specific for Hodgkin and Sternberg Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.Nature,1982,299:65-67.
[2]Stein H,Mason DY,Gerdes J,0'Conner N,Wainscoat J,Pallsen G,et al.The expression of the Hodgkin's disease associated antigen Ki-1 in reactiveand neoplastic lymphoid tissue.Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.Blood,1985,66:848-858.
[3]Schwarting R,Gerdes J,Durkop H,Falini B,Pileri S,Stein H.BER-H2:a new anti-Ki-l(CD30)monoclonal antibody directed at a formol-resistant epitope.Blood,1989,74(5):1678-89.
[4]Andreesen R,Osterholz J,Lohr GW,Bross KJ.A Hodgkin's cell-specific antigen is expressed on a subset of auto-and alloactivated T-helper.lymphoblasts.Blood,1984,63:1299-1302.
[5]Ellis TM,Simms PE,Slivnick DJ,Jack HM,Fisher RI.CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+T cellsJ Immunol,1993,151(5):2380-2389.
[6]J osimovic-Alasevic 0,Durkop H,Schwarting R,Backe E,Stein H,Diamantstein T.Ki-l(CD30)antigen is released by Ki-1-positive tumor cells in vitro and in vivo.I.Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay.Eur J Immunol,1989,19(1):157-62.
[7]Pizzolo G,Stein H,Josimovic-Alasevic 0,Vinante F,Zanotti R,Chilosi M,et al.Increased serum levels of soluble IL-2 receptor,CD30 and CD8 molecules,and gamma-interferon in angioimmunoblastic lymphadenopathy. Possible pathogenic role of immunoactivation mechanisms.Br J Haematol,1990,75:485-488.
[8]Pizzolo G,Vinante F,Chilosi M,Dallenbach F,Josimovic-Alasevic O,Diamantstein T,et al.Serum levels of soluble CD30 molecule-Ki-1 antigen in Hodgkin's diseaserrelationship with disease activity and clinical stage.Br J Haematol,1990,75:282-284.
[9]Nadali G,Vinante F,Stein H,Todeschini G,Tecchio C,Morosato L,et al.Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+anaplastic large-cell lymphoma.J Clin Oncol,1995,13:1355-1360.
[10]Caligaris-Cappio F,Bertero MT,Converso M,Stacchini A,Vinante F,Romagnani S,et al.Circulating levels of soluble CD30,a marker of cells producing Th2-type cytokines,are increased in patients with systemic lupus erythematosus and correlate with disease activity.Clin Exp Rheumatol,1995,13:339-343.
[11]Durkop H,Latza U,Hummel M,Eitelbach F,Seed B,Stein H.Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.Cell,1992,68:421-427.
[12]Smith CA,Gruss HJ,Davis T,Anderson D,Farrah T,Baker E,et al.CD30 antigen,a marker for Hodgkin's lymphoma,is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.Cell,1993,73(7):1349-60.
[13]Gruss HJ,Boiani N,Williams DE,Armitage RJ,Smith CA,Goodwin RG.Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.Blood,1994,83:2045-2056.
[14]Smith CA,Farrah T,Goodwin RG.The TNF receptor superfamily of cellular and viral proteins:activation,costimulation,and death.Cell,1994,76:959-962.
[15]Baker SJ,Reddy P.Transducers of life and death:TNF receptor superfamily and associated proteins.Oncogene,1996,12:1-9.
[16]Bazzoni F,Beutler B.The tumor necrosis factor ligand and receptor families.N Engl J Med 1996,334:1717-1725.
[17]Nawrocki JF,Kirstein ES,Fisher RI.Biochemical and structural properties of a Hodgkin's disease-related membrane protein.J Immunol,1988,141:672-680.
[18]Fonatsch C,Latza U,Durkop H,Rieder H,Stein H.Assignment of the human CD30(Ki-l)gene to lp36.Genomics,1992,14(3):825-826.
[19]Bowen MA,Lee RK,Miragliotta G,Nam SY,Podack ER.Structure and expression of murine CD30 and its role in cytokine production.J Immunol,1996,156:442-449.
[20]Aizawa S,Satoh H,Horie R,Ito K,Choi SH,Takeuchi H,et al.Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene.Gene,1996,182:155-162.
[21]Gruss HJ,Dower SK.Tumor necrosis factor ligand superfamily:Involvement in the pathology of malignant lymphomas.Blood,1995,85:3378-3404.
[22]Gedrich RW,Gilfillan MC,Duckett CS,Van Dongen JL,and Thompson CB.CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins.J Biol Chem,1996,271:12852-12858.
[23]Lee SY,Kandala G,Liou M,Liou HC,and Choi Y.CD30/TNF receptor -associated factor interaction:NF-kappa B activation and binding specificity.Proc Natl Acad Sci USA,1996,93:9699-9703.
[24]Aizawa S,Nakano H,Ishida T,Horie R,Nagai M,Ito K,et al.Tumor necrosis factor receptor-associated factor(TRAF)5 and TRAF2 are involved in CD30-mediated NF-kappaB activation.J Biol Chem,1997,272:2042-2045.
[25]Horie R,Aizawa S,Nagai M,Ito K,Higashihara M,Ishida T,et al.A novel domain in the CD30 cytoplasmic tail mediates NF-kappaB activation.Int Immunol,1998,10:203-210.
[26]Baker SJ and Reddy EP.Modulation of life and death by the TNF receptor superfamily.Oncogene,l 998,17(25):3261-3270.
[27]Tartaglia LA,Ayres TM,Wong GH and Goeddel DV.A novel domain within the 55 kd TNF receptor signals cell death.Cell,1993,74(5):845-853.
[28]Ashkenazi A and Dixit VM.Apoptosis control by death and decoy receptors.Curr Opin Cell Biol,1999,11(2):255-260.
[29]Falini B,Pileri S,Pizzolo G,Du¨rkop H,Flenghi L,Stirpe F,et al.CD30 (Ki-l)molecule:a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.Blood,1995;85:1-14.
[30]Shanebeck KD,Maliszewski CR,Kennedy MK,Picha KS,Smith CA,Goodwin RG,et al.Regulation of murine B cell growth and differentiation by CD30 ligand.Eur J Immunol,1995,25:2147-2153.
[31]Agrawal B,Reddish M,Longenecker BM.CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors.J Immunol,1996,157:3229-3234.
[32]Romagnani P,Annunziato F,Manetti R,Mavilia C,Lasagni L,Manuelli C,et al.High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus.Blood,1998,91:3323-3332.
[33]Abbondanzo SL,Sato N,Straus SE,Jaffe ES.Acute infectious mononucleosis.CD30/Ki-l antigen expression and histologic correlations.Am J Clin Pathol,1990,93:698-702.
[34]Ralfkiaer E,Bosq J,Gatter KC,Schwarting R,Gerdes J,Stein H,et al.Expression of a Hodgkin and Reed-Sternberg cell associated antigen-Ki-lin cutaneous lymphoid infiltrates.Arch Dermatol Res,1987,279:285-292.
[35]Romagnani S,Prete GD,Maggi E,Chilosi M,Caligaris-Cappio F,Pizzolo G.CD30 and type 2 T helper Th2.responses.J Leukocyte Biol,1995,57:726-730.
[36]Del Prete G,De Carli M,Almerigogna F,Danniel CK,D'Elois MM,Zancuoghi G,et al.Preferential expression of CD30 by human CD4+T cells producing Th2-type cytokines.FASEB J,1995,9:81-86.
[37]Maggi E,Giudizi MG,Biangiotti R,Annunziato F,Manetti R,Piccini MP,et al.Th2-like CD8+T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection.J Exp Med,1994,180:489-495.
[38]Manetti R,Annunziato F,Biagiotti R,Giudizi MG,Piccini MP,Giannarini L,et al.CD30 expression by CD8 T cells producing type 2 helper cytokines.Evidence for large numbers of CD8+CD30+T cell clones in human immunodeficiency virus infectionJ Exp Med,1994,180:2407-2411.
[39]Del Prete G,Maggi E,Pizzolo G,Romagnani S.CD30,Th2 cytokines and HIV infections complex and fascinating link.Immunol Today,1995,16:76-80.
[40]Hamann D,Hilkens CMU,Grogan JL,Lens SMA,Kapsenberg ML,Yazdanbakhsh M,et al.CD30 expression does not discriminate between Th1-and Th2-type T cells.J Immunol,1996,156:1387-1391.
[41][Pellegrini P,Berghella AM,Contasta I,Adorno D.CD30 antigenrnot a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.Transpl Immunol,2003,12(1):49-61.
[42]Alzona M,Jack HM,Fisher RI,Ellis TM.CD30 defines a subset of activated human T cells that produce IFN-g and IL-5 and exhibit enhanced B cell helper activity.J Immunol,1994,153:2861 -2867.
[43]Gilfillan MC,Noel PJ,Podack ER,Reiner SL,Thompson CB.Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.J Immunol,1998,160:2180-2187.
[44]Nakamura T,Lee RK,Nam SY,Al-Ramadi BK,Koni PA,Bottomly K,et al.Reciprocal regulation of CD30 expression on CD4+T cells by IL-4 and IFN-γ.J Immunol,1997,158:2090-2098.
[45]Bluestone JA.New perspectives of CD28-B7-mediated T cell costimulation.Immunity 1995,2:555-559.
[46]Brown DR,Green JM,Moskowitz NH,Davis M,Thompson CB,Reiner SL.Limited role of CD28-mediated signals in T helper subset differentiation.J Exp Med,1996,184:803-810.
[47]Ito K,Watanabe T,Horie R,Shiota M,Kawamura S,Mori S.High expression of the CD30 molecule in human decidual cells.Am J Pathol,1994,145:276-280.
[48]Shimozato 0,Takeda K,Yagita H,Okumura K.Expression of CD30 ligand (CD153)on murine activated T cells.Biochem Biophys Res Commun,1999,256:519-526.
[49]Kim MY,Gaspal FM,Wiggett HE,et al.CD4+CD3-accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells.Immunity,2003,18:643-654.
[50]Lane PJL,Gaspal FM,Kim MY.Two sides of a cellular coin.CD4+CD3-cells regulate memory responses and lymph-node organization.Nat Rev Immunol,2005,5:655-660.
[51][Younes A,Consoli U,Zhao S,Snell V,Thomas E,Gruss HJ,et al.CD30 ligand is expressed on resting normal and malignant human B lymphocytes.Br J Haematol,1996,93:569-571.
[52]Cerutti A,Schaffer A,Goodwin RG,Shah S,Zan H,EIy S,et aI.Engagement of CD153(CD30 ligand)by CD30+T cells inhibits class switch DNA recombination and antibody production in human IgD+IgM+B cells.J Immunol,2000,165:786-794.
[53]Klein U,Tu Y,Stolovitzky GA,et al.Transcriptional analysis of the B cell germinal center reaction.Proc Natl Acad Sci USA,2003,100:2639-244.
[54]Feldhahn N,Schwering I,Lee S,et al.Silencing of B cell receptor signals in human naive B cells.J Exp Med,2002,196:1291-305.
[55]Kennedy MK,Willis CR,Armitage RJ.Deciphering CD30 ligand biology and its role in humoral immunity.Immunology,2006,118(2):143-152.
[56]Takeshita M,Akamatsu M,Ohshima K,Kobari S,Kikuchi M,Suzumiya J,et al.CD30/Ki-1 expression in adult T-cell leukaemiarlymphoma is associated with distinct immunohistological and clinical characteristics.Histopathology,1995,26:539-546.
[57]Pallesen G,Hamilton-Dutoit SJK.Ki-1/CD30 antigen is regularly expressed by tumor cells of embryonal carcinoma.Am J Pathol,1988,133:446-450.
[58]Latza U,Foss HD,D¨urkop H,Eitelbach E,Dieckmann KP,Loy V,et al.CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble form.Am J Pathol,1995,146:463-471.
[59]Mechtersheimer G,Moller P.Expression of Ki-1 anti-gen_CD30.in mesenchymal tumours.Cancer,1990,66:1732-1737.
[60]Biswas P,Smith CA,Goletti D,Hardy EC,Jackson RW,Fauci AS.Cross-linking of CD30 induces HIV expression in chronically infected T cells.Immunity,1995,2:587-596.
[61]McDonald PP,Cassatella MA,Bald A,Maggi E,Romagnani S,Gruss HJ,et al.CD30 ligation induces nuclear factor-kappa B activation in human T cell lines.Eur J Immunol,1995,25:2870-2876.
[62]Gr'uss HJ,Hermann F.CD30 ligand,a member of the TNF ligand superfamily,with growth and activation control for CD30+lymphoid and lymphoma cells.Leukemia lymphoma,1996,20:397-409.
[63]Maggi E,Annunziato F,Manetti R,Biagiotti R,Giudizi MG,Ravina A,et al.Activation of HIV expression by CD30 triggering in CD4+T cells from HIV-infected individuals.Immunity,1995,3:251-255.
[64]Gr¨uss HJ,Scheffrahn I,Hubinger G,Duyster J,Hermann F.The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.Leukemia,1996,10:829-835.
[65][Gr¨uss HJ,Ulrich D,Dower SK,Herrmann F,Brach MA.Activation of Hodgkin cells via the CD30 receptor induced autocrine secretion of interleukin-6 engaging the NF-kB transcription factor.Blood,1996,87:2443-2449.
[66]Malinin NL,Boldin MP,Kovalenko AV,Wallach D.MAP3K-related kinase involved in NF-kB induction by TNF,CD95 and IL-l.Nature,1997,385:540-544.
[67]Hu HM,O'Rourke K,Boguski MS,Dixit VM.A novel RING finger protein interacts with the cytoplasmic domain of CD40.J Biol Chem,1994,269:30069-30072.
[68]Rothe M,Wong SC,Henzel WJ,Goeddel DV.A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor.Cell,1994,78:681-692.
[69]Cheng G,Cleary AM,Ye ZS,Hong DI,Lederman S,BaIti-more D.Involvement of CRAFl,a relative of TRAF,in CD40 signaling.Science, 1995,267:1494-1498.
[70]Mosialos G,Birkenbach M,Yalamachili R,VanArsdale T,Ware C,Kieff E.The Epstein-Barr virus transforming protein LMP1 engages signal proteins for the tumor necrosis factor receptor family.Cell,1995,80:389-399.
[71]Regnier CH,Tomasetto C,Moog-Lutz C,Chenard MP,Wendling C,Basset P,et al.Presence of a new conserved domain in CARTl,a novel member of the tumor necrosis factor receptor-associated protein family,which is expressed in breast carcinoma.J Biol Chem,1995,270:25715-25721.
[72]Sato T,Irie S,Reed JC.A novel member of the TRAF family of putative signal transducing proteins binds to the cytoplasmic domain of CD40.FEBS Lett,1995,358:113-118.
[73]Song HY,Donner DB.Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumor necrosis factor.Biochem J,1995,809:825-829.
[74]Nakano H,Oshima H,Chung W,Williams-Abbott L,Ware CF,Yagita H,et al.TRAF5,an activator of NF-k B and putative signal transducer for the lymphotoxinbeta receptor.J Biol Chem,1996,271:14661-14664.
[75]Ishida T,Tojo T,Aoki T,Kobayashi N,Ohishi T,Watanabe T,et al.TRAF-5,a novel TRAF family protein,mediates CD40 signaling.Proc Natl Acad Sci,1996,93:9437-9442.
[76]Cao Z,Xiong J,Takeuchi M,Kurama T,Goeddel DV.TRAF6 is a signal transducer for interleukin 1.Nature,1996,383:443-446.
[77]Ishida T,Mizushima S,Kobayashi N,Tojo T,Aizawa S,Watanabe T,et al.Identification of TRAF6,a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.J Biol Chem,1996,271:28745-28748.
[78]Duckett CS,Gedrich RW,Gilfillan MC,Thompson CB.Induction of nuclear factoncB by the CD30 receptor is ediated by TRAF1 and TRAF2.Mol Cell Biol,1997,17:1535-1542.
[79]Tsitsikov E,Wright DA,Geha RS.CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.Proc Natl Acad Sci,1997,94:1390-1395.
[80]Duckett CS,Thompson CB.CD30-dependent degradation of TRAF2:implications for negative regulation of TRAF signaling and the control of cell survival.Gene Dev,1997,11:2810-2821.
[81]Hsu H,Solovyev I,Colomero A,Elliot R,Kelly M,Boyle WJ.ATAR,a novel tumor necrosis factor receptor family member,signals through TRAF2 and TRAF5.J Biol Chem,1997,272:13471-13474.
[82]Marsters SA,Ayres TM,Skubatch M,Gray CL,Rothe M,Ashkenazi A.Herpes entry mediatory member of the tumor necrosis factor receptor (TNFR)family,interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kB and AP-1.J Biol Chem,1997,272:14029-14032.
[83]Kawamata S,Hori T,Imura A,Takaori-Kondo A,Uchiyama T.Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor(TRAF)-2 and TRAF5-mediated NF-kB activation.J Biol Chem,1998,273:5808-5814.
[84]Akiba H,Nakano H,Nishinaka S,Shindo M,Kobata T,Atsuta M,et al.CD27,a member of the tumor necrosis factor receptor superfamily,activates NF-kB and stress-activated protein kinaser c-Jun N-terminal kinase via TRAF2,TRAF5,and NF-KB-inducing kinase.J Biol Chem,1998,273:13353-13358.
[85]Mercurio F,Zhu H,Murray BW,Shevchenko A,Bennett BL,Li JW,et al.IKK1 and IKK2:Cytokine-activated IkB kinases essential for NF-κB activation.Science,1997,278:860-866.
[86]Woronicz JD,Gao X,Cao Z,Rothe.M,Goeddel DV.IκB kinase-b:NF-κB activation and complex formation with IκB kinase-a and NIK.Science,1997,278:866-869.
[87]Nakano H,Shindo M,Sakon S,Nishikawa S,Mihara M,Yagita H,et al.Differential regulation of IκB kinase a and b by two upstream kinases,NF-κB-inducing kinase and mitogen-activated protein kinaser ERK kinase-1.Proc Natl Acad Sci,1998,95:3537-3542.
[88]Lee FS,Hagler J,Chen ZJ,Maniatis T.Activation the IkB kinase complex by MEKK1,a kinase of the JNK pathway.Cell,1997,88:213-222.
[89]Song HY,Regnier C,Kirschning CJ,Goeddel DV,Rothe M.1997.Tumor necrosis factor(TNF)-mediated kinase cascades:bifurcation of nuclear factor-κB and c-jun N-terminal kinase(JNK)SAPK.pathways at TNF receptor-associated factor 2.Proc Natl Acad Sci,94:9792-9796.
[90]Natoli G,Costanzo A,Moretti F,Fulco M,Balsano C,Levrero M.Tumor necrosis factor(TNF)receptor signaling downstream of TNF receptor-associated factor 2:nuclear factond3(NF-κB)-inducing kinase requirement for activation of activating protein 1 and NF-κB but not of c-jun N-terminal kinaserstress-activated protein kinase.J Biol Chem,1997,272:26079-26082.
[91]Lee SY,Reichlin A,Santana A,Sokol KA,Nussenzweig MC,Choi Y.TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival.Immunity,1997,7:703-713.
[92]Schneider C,Stohr D,Merz H,Hubinger G.Signal transduction in anaplastic large cell lymphoma cells(ALCL)mediated by the tumor necrosis factor receptor CD30.Leuk Lymphoma,2004,45(5):1009-1015.
[93]Croft M.Co-stimulatory members of the TNFR family:keys to effective T-cell immunity?Nat Rev Immunol,2003,3:609-3620.
[94]Eissner G,Kolch W,Scheurich P.Ligands working as receptors.reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.Cytokine Growth Factor Rev,2004,15:353-366.
[95]Jumper MD,Nishioka Y,Davis LS,Lipsky PE,Meek K.Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands.J Immunol,1995,155:2369-2378.
[96]Cerutti A,Schaffer A,Shah S,Zan H,Liou HC,Goodwin RG,et al.CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells.Immunity,1998,9:247-256.
[97]Cerutti A,Kim EC,Shah S,Schattner EJ,Zan H,Schaffer A,et al.Dysregulation of CD30+T cells by leukemia impairs isotype switching in normal B cells.[Erratum appears in Nat Immunol,2001, 2(4):368].NatImmunol,2001,2:150-156.
[98]Amakawa R,Hakem A,Kundig TM et al.Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice.Cell,1996,84:551-562.
[99]Kishimoto H,Sprent J.Several different cell surface molecules control negative selection of medullary thymocytes.J Exp Med,1999;190:65-73.
[100]De Young AL,Duramad 0,Winoto A.The TNF receptor family member CD30 is not essential for negative selection.J Immunol,2000,165:6170-6173.
[101]Flo'rido M,Borges M,Yagita H,Appelberg R.Contribution of CD30/CD153 but not of CD27/CD70,CD134/OX40L,or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.J Leukoc Biol,2004,76:1039-1046.
[102]Kurts C,Carbone FR,Krummel MF,Koch KM,Miller JF,Heath WR.Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.[Erratum appears in Nature,2000,407:413].Nature,1999,398:341-344.
[103]Heath WR,Kurts C,Caminschi I,Carbone FR,Miller JF.CD30 prevents T-cell responses to non-lymphoid tissues.Immunol Rev,1999,169:23-29.
[104]Kurts C,Carbone FR,Krummel MF,Koch KM,Miller JFAP,Heath WR.Correction:signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.Nature,2000,407:413.
[105]Gaspal FM,Kim MY,McConnell FM,Raykundalia C,Bekiaris V,Lane PJ.Mice deficient in OX40 and CD30 signals lack memory antibody responsesbecause of deficient CD4 T cell memory.J Immunol,2005,l 74:3891-3896.
[106]Blazar BR,Levy RB,Mak TW,et al.CD30/CD30 ligand(CD153) interaction regulates CD4+T cell-mediated graft-versus-host disease.J Immunol,2004,173:2933-2941.
[107]Podack ER,Strbo N,Sotosec V,Muta H.CD30-governor of memory T cells? Ann NY Acad Sci,2002,975:101-113.
[108]Susal C,Pelzl S,Dohler B,Opelz G.Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30.J Am Soc Nephrol,2002,13(6):1650-1656.
[109]Pelzl S,Opelz G,Daniel V,Wiesel M,Susal C.Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection.Transplantation,2003,75(3):421-423.
[110]Dong W,Shunliang Y,Weizhen W,Qinghua W,Zhangxin ZJianming T,He W.Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30.Transpl Immuno,l 2006,16(1):41.
[111]Susal C,Pelzl S,Simon T,et al.Advances in pre and posttransplant immunologic testing in kidney transplantation.Transplant Proc,2004,36:29-34.
[112]Pelzl S,Opelz G,WieselM,et al.Soluble CD30 as a predictor of kidney graft outcome.Transplantation,2002,73:3-6.
[113]Susal C,Pelzl S.Strang human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble cd30.Transplantation,2003576(8):1231-1232.
[114]Barth S,Huhn M.Ki-4(scFv)-ETA',a new recombinant anti-CD30immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.Blood,2000,95(12):3909-3914.
[115]Schuurman HJ,Cheng J,Lam T.Pathology of xenograft rejectionra commentary.Xenotransplantation,2003,10:293-299.
[116]PascualM,Vallhonrat H,Cosimi AB,et al.The clinical usefulness of the renal allograft biopsy in the cyclosporine era:a p rospective study.Transplantation,1999,67:737-741.
[117]Susal C,Pelzl S,Opelz G.High pretransp lant serum sCD30 content as a possible explanation for the high rejection rate in young kidney graft recipients.Pediatr Transplant,2003,7:48-49.
[118]Nakao K,Nagake Y,Okamoto A,et al.Serum levels of soluble CD26 and CD30 inpatients onhemodialysis.Nephron,2002,91:215-221.
[2]文吉秋,季曙明.慢性移植肾功能不全的原因与防治.肾脏病与透析肾移植杂志[J].2005,14:568-573.
[3]Terasaki PI.Humoral theory of transplantation.Am J Transplant,2003,3:665-673.
[4]Cai J,Terasaki PI.Humoral theory of transplantation:mechanism,prevention,and treatment.Hum Immunol.2005,66:334-342.
[5]Sureshumar KK,Hussain SM,Carpenter BJ,et al.Antibody-mediated rejection follwoong renal transplantation.Expert Opin Pharmacother,2007,8:913-921.
[6]Regele H,Exner M,Watschinger B,et al.Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection.Nephrol Dial Transplant,2001,16(10):2058-2066.
[7]Regele H,Bohmig GA,Haicht A,et al.Capillary deosition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries:A contribution of humoral immunity to chronic allograft rejection.J Am Soc Nephrol,2002,13(9):2371-2380.
[8]Collins AB,Schneeberger EE,Pascual MA,et al.Complemen activation in acute humoral renal allograft rejection:diagnostic significance of C4d deposits in peritubular capillaries.J Am Soc Nephrol,1999,10(10):2208-2214.
[9]Mosmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell.J Immunol,1986,136(7):2348-2357.[]
[10]Maggie E,Biswar R,Pnete GD,et al.Accumulation of Th2 like helper T cells in the conjunctiva of patients with vernal conjunctivitis.J Immunol,1991,146:1169-1174.
[11]Durkop H,Latza U.Molecular cloning and expression of a new member of the nerve groth factor receptor family that is characteristic for Hodgkin's disease.Cell, 1992,68:421-427.
[12]Del Prete G et al.Preferential expression of CD30 by human CD4+T cells producing Th2-type cytokines.FASEB J,1995,9:81.
[13]Romagnani S,Del Prete G,et al.CD30 and type 2 T-helper(Th2)responses.J Leukoc Biol,1995,57:726-730.
[14]Rebhandl W,Felberbauer FX,Rwsch S,et al.Value of circulating immune parameters in renal transplantation.Transplant Proc,1997,29:1881.
[15]SUSAL C,PELZL S,SIMON T,et al.Advances in pre- and post-transplant immunologic testing in kidney transplantation[J].Transplantation Proc,2004,36:29-34.
[16]SUSAL C,PELZL S,DOHLER B,et al.Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30[J].J Am Soc Neprol,2002,13:1650-1656.
[17]McMillan SA,McDonnell GV,et al.Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis.Neurology,1998,51:1156-1160.
[18]PELZL S,OPELZ G,DANNIEL V,et al.Evaluation of post-transplantati on soluble CD30 for diagnosis of acute renal allograft rejection[J].Transplantation,2003,75:421-423.
[19]PELZL S,OPELZ G,WIESEL M,et al.Soluble CD30 as a predictor of kidney allograft outcome[J].Transplantation ,2002,73:3-6.
[20]SUSAL C,PELZL S,OPELZ G.Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.Transplantation,2003,76:1231-1232.
[21 ]Barth S,Huhn M.Ki-4(scFv)-ETA,a new recombinant anti-CD30 immunotoxin Nscid mice.Blood,2000,95:3909-3914.
[22]Gebel HM,Bray RA,Nickerson P.Pre-transplant assessment of donor-reactive,HLA-specific antibodies in renal transplantation:contraindication vs.risk.Am J Transplant,2003,3( 12):1488-1500.
[23]Kennedy MK,Willis CR,Armitage RJ.Deciphering CD30 ligand biologyand its role in humoral immunity.Immunology,2006,118(2):143-152.
[1]Montgomery RA,Hardy MA,Jordan,SC,et al.Consensus opinion from the antibody working group on the diagnosis,reporting,and risk assessment for antibody-mediated rejection and desensitization protocols.Transplantation,2004,78:181_185.
[2]Terasaki PI.Humoral theory of transplantation.Am J Transplant,2003,3:665-673.
[3]Racusen LC,Colvin RB,Solez K,et al.Antibody-mediated rejection criteria an addition to Banff 97 classification of renal allograft rejection.Am J Transplant,2003,3:708-714.
[4]Colvin RB,Smith RN.Antibody mediated organ allograft rejection.Nature Rev.Immunol,2005,5:807-817.
[5]Sumitran-Holgersson S,Wilczek HE,Holgersson J,et al.Identification of the nonclassical HLA molecules MICA,as targets for humoral immunity associated with irreversible rejection of kidney allografts.Transplantation,2002,74:268-277.
[6]Dragun D,M ller DN,B r sen JH,et al.Angiotensin Ⅱ type-receptor-activiating antibodies in renal-allograft rejection.N Engl J Med,2005,352:558-569.
[7]Sun Qiquan,Liu Zhihong,Yin Guang,et al.Detectable circulating antiendothelial cell antibodies in renal-allograft recipient with C4d positive acute rejection:a report of three cases.Transplantation,2005,79:1759-1762.
[8]谭建明,周永昌,唐孝达,主编.组织配型技术与临床应用.第1版.人民卫生出版社,2002.
[9]Desvaux D,Le-Gouvello S,Pastural M,et al.Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates:high gamma-interferon expressoin andpoor clinical outcome.Nephrol Dial Transplant,2004,19:933-939.
[10]Baldwin WM,Kasper EK,Zachary AA,et al.Beyond C4d:other complement-related diagnositic approaches to antibody-mediated rejection.Am J Transplant,2004,4:311-318.
[11]Sacks SH,Chowdhury P,Zhou W.Role of the complement system in rejection.Curr Oppin Immunol,2003,15:487-492.
[12]Lepin EJ,Reed EF.Complement-independent mechanisms of antigraft antibodies in transplant arteriosclerosis and accommodation.Curr Opin Organ Transplant,2004,9:10-15.
[13]Mauiyyedi S,Crespo M,Collins AB,et al.Acute humoral rejection in kidney tranplanttation:Ⅱ Morphology,immuno-pathology,and pathologic classification.J Am Soc Nephrol,2002,13:779-787.
[14]Takemoto SK,Zeevl A,Feng S,et al.National conference to assess antibody-mediated rejection in solid organ transplantation.Am J Transplant,2004,12:2482-2489.
[15]Bohmig GA,Regele H,Exner M,et al.C4d-positive acute humoral renal allograft rejection:effective treatment by immunoadsortion.J Am Soc Nephrol,2001,12:2482-2489.
[16]Pascual M,Saidman S,Tolkoff-Rubin N,et al.Plasma exchange and tarcrolimus-mycophenolate rescue for acute humoral rejection.Curr Oppin ogan Transplant,2004,9:29-35.
[17]Montgomery RA,Zachary AA,Racusen LC,et al.Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch positive recipients.Transplantation,2000,70:889-895.
[18]Rocha PN,Butterly DW,Greenberg A,et al.Beneficial effects of plasmapheresis and intravenous immune globulin on renal allograft survival of patients with acute humoral rejection.Transplantation,2003,75:1490-1495.
[19]Jordan SC,Vo A,Bunnap radist S,et al.Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.Transplantation,76:631-636.
[20]Frank MM,Miletic VD,Jiang H.Immunoglobulin in the control of complement action.Immunol Res,2000,22:137-146.
[1]Schwab U,Stein H,Gerdes J,Lemke H,Kirchner H,Schaadt M,et al.Production of a monoclonal antibody specific for Hodgkin and Sternberg Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.Nature,1982,299:65-67.
[2]Stein H,Mason DY,Gerdes J,0'Conner N,Wainscoat J,Pallsen G,et al.The expression of the Hodgkin's disease associated antigen Ki-1 in reactiveand neoplastic lymphoid tissue.Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.Blood,1985,66:848-858.
[3]Schwarting R,Gerdes J,Durkop H,Falini B,Pileri S,Stein H.BER-H2:a new anti-Ki-l(CD30)monoclonal antibody directed at a formol-resistant epitope.Blood,1989,74(5):1678-89.
[4]Andreesen R,Osterholz J,Lohr GW,Bross KJ.A Hodgkin's cell-specific antigen is expressed on a subset of auto-and alloactivated T-helper.lymphoblasts.Blood,1984,63:1299-1302.
[5]Ellis TM,Simms PE,Slivnick DJ,Jack HM,Fisher RI.CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+T cellsJ Immunol,1993,151(5):2380-2389.
[6]J osimovic-Alasevic 0,Durkop H,Schwarting R,Backe E,Stein H,Diamantstein T.Ki-l(CD30)antigen is released by Ki-1-positive tumor cells in vitro and in vivo.I.Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay.Eur J Immunol,1989,19(1):157-62.
[7]Pizzolo G,Stein H,Josimovic-Alasevic 0,Vinante F,Zanotti R,Chilosi M,et al.Increased serum levels of soluble IL-2 receptor,CD30 and CD8 molecules,and gamma-interferon in angioimmunoblastic lymphadenopathy. Possible pathogenic role of immunoactivation mechanisms.Br J Haematol,1990,75:485-488.
[8]Pizzolo G,Vinante F,Chilosi M,Dallenbach F,Josimovic-Alasevic O,Diamantstein T,et al.Serum levels of soluble CD30 molecule-Ki-1 antigen in Hodgkin's diseaserrelationship with disease activity and clinical stage.Br J Haematol,1990,75:282-284.
[9]Nadali G,Vinante F,Stein H,Todeschini G,Tecchio C,Morosato L,et al.Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+anaplastic large-cell lymphoma.J Clin Oncol,1995,13:1355-1360.
[10]Caligaris-Cappio F,Bertero MT,Converso M,Stacchini A,Vinante F,Romagnani S,et al.Circulating levels of soluble CD30,a marker of cells producing Th2-type cytokines,are increased in patients with systemic lupus erythematosus and correlate with disease activity.Clin Exp Rheumatol,1995,13:339-343.
[11]Durkop H,Latza U,Hummel M,Eitelbach F,Seed B,Stein H.Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.Cell,1992,68:421-427.
[12]Smith CA,Gruss HJ,Davis T,Anderson D,Farrah T,Baker E,et al.CD30 antigen,a marker for Hodgkin's lymphoma,is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.Cell,1993,73(7):1349-60.
[13]Gruss HJ,Boiani N,Williams DE,Armitage RJ,Smith CA,Goodwin RG.Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.Blood,1994,83:2045-2056.
[14]Smith CA,Farrah T,Goodwin RG.The TNF receptor superfamily of cellular and viral proteins:activation,costimulation,and death.Cell,1994,76:959-962.
[15]Baker SJ,Reddy P.Transducers of life and death:TNF receptor superfamily and associated proteins.Oncogene,1996,12:1-9.
[16]Bazzoni F,Beutler B.The tumor necrosis factor ligand and receptor families.N Engl J Med 1996,334:1717-1725.
[17]Nawrocki JF,Kirstein ES,Fisher RI.Biochemical and structural properties of a Hodgkin's disease-related membrane protein.J Immunol,1988,141:672-680.
[18]Fonatsch C,Latza U,Durkop H,Rieder H,Stein H.Assignment of the human CD30(Ki-l)gene to lp36.Genomics,1992,14(3):825-826.
[19]Bowen MA,Lee RK,Miragliotta G,Nam SY,Podack ER.Structure and expression of murine CD30 and its role in cytokine production.J Immunol,1996,156:442-449.
[20]Aizawa S,Satoh H,Horie R,Ito K,Choi SH,Takeuchi H,et al.Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene.Gene,1996,182:155-162.
[21]Gruss HJ,Dower SK.Tumor necrosis factor ligand superfamily:Involvement in the pathology of malignant lymphomas.Blood,1995,85:3378-3404.
[22]Gedrich RW,Gilfillan MC,Duckett CS,Van Dongen JL,and Thompson CB.CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins.J Biol Chem,1996,271:12852-12858.
[23]Lee SY,Kandala G,Liou M,Liou HC,and Choi Y.CD30/TNF receptor -associated factor interaction:NF-kappa B activation and binding specificity.Proc Natl Acad Sci USA,1996,93:9699-9703.
[24]Aizawa S,Nakano H,Ishida T,Horie R,Nagai M,Ito K,et al.Tumor necrosis factor receptor-associated factor(TRAF)5 and TRAF2 are involved in CD30-mediated NF-kappaB activation.J Biol Chem,1997,272:2042-2045.
[25]Horie R,Aizawa S,Nagai M,Ito K,Higashihara M,Ishida T,et al.A novel domain in the CD30 cytoplasmic tail mediates NF-kappaB activation.Int Immunol,1998,10:203-210.
[26]Baker SJ and Reddy EP.Modulation of life and death by the TNF receptor superfamily.Oncogene,l 998,17(25):3261-3270.
[27]Tartaglia LA,Ayres TM,Wong GH and Goeddel DV.A novel domain within the 55 kd TNF receptor signals cell death.Cell,1993,74(5):845-853.
[28]Ashkenazi A and Dixit VM.Apoptosis control by death and decoy receptors.Curr Opin Cell Biol,1999,11(2):255-260.
[29]Falini B,Pileri S,Pizzolo G,Du¨rkop H,Flenghi L,Stirpe F,et al.CD30 (Ki-l)molecule:a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.Blood,1995;85:1-14.
[30]Shanebeck KD,Maliszewski CR,Kennedy MK,Picha KS,Smith CA,Goodwin RG,et al.Regulation of murine B cell growth and differentiation by CD30 ligand.Eur J Immunol,1995,25:2147-2153.
[31]Agrawal B,Reddish M,Longenecker BM.CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors.J Immunol,1996,157:3229-3234.
[32]Romagnani P,Annunziato F,Manetti R,Mavilia C,Lasagni L,Manuelli C,et al.High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus.Blood,1998,91:3323-3332.
[33]Abbondanzo SL,Sato N,Straus SE,Jaffe ES.Acute infectious mononucleosis.CD30/Ki-l antigen expression and histologic correlations.Am J Clin Pathol,1990,93:698-702.
[34]Ralfkiaer E,Bosq J,Gatter KC,Schwarting R,Gerdes J,Stein H,et al.Expression of a Hodgkin and Reed-Sternberg cell associated antigen-Ki-lin cutaneous lymphoid infiltrates.Arch Dermatol Res,1987,279:285-292.
[35]Romagnani S,Prete GD,Maggi E,Chilosi M,Caligaris-Cappio F,Pizzolo G.CD30 and type 2 T helper Th2.responses.J Leukocyte Biol,1995,57:726-730.
[36]Del Prete G,De Carli M,Almerigogna F,Danniel CK,D'Elois MM,Zancuoghi G,et al.Preferential expression of CD30 by human CD4+T cells producing Th2-type cytokines.FASEB J,1995,9:81-86.
[37]Maggi E,Giudizi MG,Biangiotti R,Annunziato F,Manetti R,Piccini MP,et al.Th2-like CD8+T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection.J Exp Med,1994,180:489-495.
[38]Manetti R,Annunziato F,Biagiotti R,Giudizi MG,Piccini MP,Giannarini L,et al.CD30 expression by CD8 T cells producing type 2 helper cytokines.Evidence for large numbers of CD8+CD30+T cell clones in human immunodeficiency virus infectionJ Exp Med,1994,180:2407-2411.
[39]Del Prete G,Maggi E,Pizzolo G,Romagnani S.CD30,Th2 cytokines and HIV infections complex and fascinating link.Immunol Today,1995,16:76-80.
[40]Hamann D,Hilkens CMU,Grogan JL,Lens SMA,Kapsenberg ML,Yazdanbakhsh M,et al.CD30 expression does not discriminate between Th1-and Th2-type T cells.J Immunol,1996,156:1387-1391.
[41][Pellegrini P,Berghella AM,Contasta I,Adorno D.CD30 antigenrnot a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.Transpl Immunol,2003,12(1):49-61.
[42]Alzona M,Jack HM,Fisher RI,Ellis TM.CD30 defines a subset of activated human T cells that produce IFN-g and IL-5 and exhibit enhanced B cell helper activity.J Immunol,1994,153:2861 -2867.
[43]Gilfillan MC,Noel PJ,Podack ER,Reiner SL,Thompson CB.Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.J Immunol,1998,160:2180-2187.
[44]Nakamura T,Lee RK,Nam SY,Al-Ramadi BK,Koni PA,Bottomly K,et al.Reciprocal regulation of CD30 expression on CD4+T cells by IL-4 and IFN-γ.J Immunol,1997,158:2090-2098.
[45]Bluestone JA.New perspectives of CD28-B7-mediated T cell costimulation.Immunity 1995,2:555-559.
[46]Brown DR,Green JM,Moskowitz NH,Davis M,Thompson CB,Reiner SL.Limited role of CD28-mediated signals in T helper subset differentiation.J Exp Med,1996,184:803-810.
[47]Ito K,Watanabe T,Horie R,Shiota M,Kawamura S,Mori S.High expression of the CD30 molecule in human decidual cells.Am J Pathol,1994,145:276-280.
[48]Shimozato 0,Takeda K,Yagita H,Okumura K.Expression of CD30 ligand (CD153)on murine activated T cells.Biochem Biophys Res Commun,1999,256:519-526.
[49]Kim MY,Gaspal FM,Wiggett HE,et al.CD4+CD3-accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells.Immunity,2003,18:643-654.
[50]Lane PJL,Gaspal FM,Kim MY.Two sides of a cellular coin.CD4+CD3-cells regulate memory responses and lymph-node organization.Nat Rev Immunol,2005,5:655-660.
[51][Younes A,Consoli U,Zhao S,Snell V,Thomas E,Gruss HJ,et al.CD30 ligand is expressed on resting normal and malignant human B lymphocytes.Br J Haematol,1996,93:569-571.
[52]Cerutti A,Schaffer A,Goodwin RG,Shah S,Zan H,EIy S,et aI.Engagement of CD153(CD30 ligand)by CD30+T cells inhibits class switch DNA recombination and antibody production in human IgD+IgM+B cells.J Immunol,2000,165:786-794.
[53]Klein U,Tu Y,Stolovitzky GA,et al.Transcriptional analysis of the B cell germinal center reaction.Proc Natl Acad Sci USA,2003,100:2639-244.
[54]Feldhahn N,Schwering I,Lee S,et al.Silencing of B cell receptor signals in human naive B cells.J Exp Med,2002,196:1291-305.
[55]Kennedy MK,Willis CR,Armitage RJ.Deciphering CD30 ligand biology and its role in humoral immunity.Immunology,2006,118(2):143-152.
[56]Takeshita M,Akamatsu M,Ohshima K,Kobari S,Kikuchi M,Suzumiya J,et al.CD30/Ki-1 expression in adult T-cell leukaemiarlymphoma is associated with distinct immunohistological and clinical characteristics.Histopathology,1995,26:539-546.
[57]Pallesen G,Hamilton-Dutoit SJK.Ki-1/CD30 antigen is regularly expressed by tumor cells of embryonal carcinoma.Am J Pathol,1988,133:446-450.
[58]Latza U,Foss HD,D¨urkop H,Eitelbach E,Dieckmann KP,Loy V,et al.CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble form.Am J Pathol,1995,146:463-471.
[59]Mechtersheimer G,Moller P.Expression of Ki-1 anti-gen_CD30.in mesenchymal tumours.Cancer,1990,66:1732-1737.
[60]Biswas P,Smith CA,Goletti D,Hardy EC,Jackson RW,Fauci AS.Cross-linking of CD30 induces HIV expression in chronically infected T cells.Immunity,1995,2:587-596.
[61]McDonald PP,Cassatella MA,Bald A,Maggi E,Romagnani S,Gruss HJ,et al.CD30 ligation induces nuclear factor-kappa B activation in human T cell lines.Eur J Immunol,1995,25:2870-2876.
[62]Gr'uss HJ,Hermann F.CD30 ligand,a member of the TNF ligand superfamily,with growth and activation control for CD30+lymphoid and lymphoma cells.Leukemia lymphoma,1996,20:397-409.
[63]Maggi E,Annunziato F,Manetti R,Biagiotti R,Giudizi MG,Ravina A,et al.Activation of HIV expression by CD30 triggering in CD4+T cells from HIV-infected individuals.Immunity,1995,3:251-255.
[64]Gr¨uss HJ,Scheffrahn I,Hubinger G,Duyster J,Hermann F.The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.Leukemia,1996,10:829-835.
[65][Gr¨uss HJ,Ulrich D,Dower SK,Herrmann F,Brach MA.Activation of Hodgkin cells via the CD30 receptor induced autocrine secretion of interleukin-6 engaging the NF-kB transcription factor.Blood,1996,87:2443-2449.
[66]Malinin NL,Boldin MP,Kovalenko AV,Wallach D.MAP3K-related kinase involved in NF-kB induction by TNF,CD95 and IL-l.Nature,1997,385:540-544.
[67]Hu HM,O'Rourke K,Boguski MS,Dixit VM.A novel RING finger protein interacts with the cytoplasmic domain of CD40.J Biol Chem,1994,269:30069-30072.
[68]Rothe M,Wong SC,Henzel WJ,Goeddel DV.A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor.Cell,1994,78:681-692.
[69]Cheng G,Cleary AM,Ye ZS,Hong DI,Lederman S,BaIti-more D.Involvement of CRAFl,a relative of TRAF,in CD40 signaling.Science, 1995,267:1494-1498.
[70]Mosialos G,Birkenbach M,Yalamachili R,VanArsdale T,Ware C,Kieff E.The Epstein-Barr virus transforming protein LMP1 engages signal proteins for the tumor necrosis factor receptor family.Cell,1995,80:389-399.
[71]Regnier CH,Tomasetto C,Moog-Lutz C,Chenard MP,Wendling C,Basset P,et al.Presence of a new conserved domain in CARTl,a novel member of the tumor necrosis factor receptor-associated protein family,which is expressed in breast carcinoma.J Biol Chem,1995,270:25715-25721.
[72]Sato T,Irie S,Reed JC.A novel member of the TRAF family of putative signal transducing proteins binds to the cytoplasmic domain of CD40.FEBS Lett,1995,358:113-118.
[73]Song HY,Donner DB.Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumor necrosis factor.Biochem J,1995,809:825-829.
[74]Nakano H,Oshima H,Chung W,Williams-Abbott L,Ware CF,Yagita H,et al.TRAF5,an activator of NF-k B and putative signal transducer for the lymphotoxinbeta receptor.J Biol Chem,1996,271:14661-14664.
[75]Ishida T,Tojo T,Aoki T,Kobayashi N,Ohishi T,Watanabe T,et al.TRAF-5,a novel TRAF family protein,mediates CD40 signaling.Proc Natl Acad Sci,1996,93:9437-9442.
[76]Cao Z,Xiong J,Takeuchi M,Kurama T,Goeddel DV.TRAF6 is a signal transducer for interleukin 1.Nature,1996,383:443-446.
[77]Ishida T,Mizushima S,Kobayashi N,Tojo T,Aizawa S,Watanabe T,et al.Identification of TRAF6,a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.J Biol Chem,1996,271:28745-28748.
[78]Duckett CS,Gedrich RW,Gilfillan MC,Thompson CB.Induction of nuclear factoncB by the CD30 receptor is ediated by TRAF1 and TRAF2.Mol Cell Biol,1997,17:1535-1542.
[79]Tsitsikov E,Wright DA,Geha RS.CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.Proc Natl Acad Sci,1997,94:1390-1395.
[80]Duckett CS,Thompson CB.CD30-dependent degradation of TRAF2:implications for negative regulation of TRAF signaling and the control of cell survival.Gene Dev,1997,11:2810-2821.
[81]Hsu H,Solovyev I,Colomero A,Elliot R,Kelly M,Boyle WJ.ATAR,a novel tumor necrosis factor receptor family member,signals through TRAF2 and TRAF5.J Biol Chem,1997,272:13471-13474.
[82]Marsters SA,Ayres TM,Skubatch M,Gray CL,Rothe M,Ashkenazi A.Herpes entry mediatory member of the tumor necrosis factor receptor (TNFR)family,interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kB and AP-1.J Biol Chem,1997,272:14029-14032.
[83]Kawamata S,Hori T,Imura A,Takaori-Kondo A,Uchiyama T.Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor(TRAF)-2 and TRAF5-mediated NF-kB activation.J Biol Chem,1998,273:5808-5814.
[84]Akiba H,Nakano H,Nishinaka S,Shindo M,Kobata T,Atsuta M,et al.CD27,a member of the tumor necrosis factor receptor superfamily,activates NF-kB and stress-activated protein kinaser c-Jun N-terminal kinase via TRAF2,TRAF5,and NF-KB-inducing kinase.J Biol Chem,1998,273:13353-13358.
[85]Mercurio F,Zhu H,Murray BW,Shevchenko A,Bennett BL,Li JW,et al.IKK1 and IKK2:Cytokine-activated IkB kinases essential for NF-κB activation.Science,1997,278:860-866.
[86]Woronicz JD,Gao X,Cao Z,Rothe.M,Goeddel DV.IκB kinase-b:NF-κB activation and complex formation with IκB kinase-a and NIK.Science,1997,278:866-869.
[87]Nakano H,Shindo M,Sakon S,Nishikawa S,Mihara M,Yagita H,et al.Differential regulation of IκB kinase a and b by two upstream kinases,NF-κB-inducing kinase and mitogen-activated protein kinaser ERK kinase-1.Proc Natl Acad Sci,1998,95:3537-3542.
[88]Lee FS,Hagler J,Chen ZJ,Maniatis T.Activation the IkB kinase complex by MEKK1,a kinase of the JNK pathway.Cell,1997,88:213-222.
[89]Song HY,Regnier C,Kirschning CJ,Goeddel DV,Rothe M.1997.Tumor necrosis factor(TNF)-mediated kinase cascades:bifurcation of nuclear factor-κB and c-jun N-terminal kinase(JNK)SAPK.pathways at TNF receptor-associated factor 2.Proc Natl Acad Sci,94:9792-9796.
[90]Natoli G,Costanzo A,Moretti F,Fulco M,Balsano C,Levrero M.Tumor necrosis factor(TNF)receptor signaling downstream of TNF receptor-associated factor 2:nuclear factond3(NF-κB)-inducing kinase requirement for activation of activating protein 1 and NF-κB but not of c-jun N-terminal kinaserstress-activated protein kinase.J Biol Chem,1997,272:26079-26082.
[91]Lee SY,Reichlin A,Santana A,Sokol KA,Nussenzweig MC,Choi Y.TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival.Immunity,1997,7:703-713.
[92]Schneider C,Stohr D,Merz H,Hubinger G.Signal transduction in anaplastic large cell lymphoma cells(ALCL)mediated by the tumor necrosis factor receptor CD30.Leuk Lymphoma,2004,45(5):1009-1015.
[93]Croft M.Co-stimulatory members of the TNFR family:keys to effective T-cell immunity?Nat Rev Immunol,2003,3:609-3620.
[94]Eissner G,Kolch W,Scheurich P.Ligands working as receptors.reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.Cytokine Growth Factor Rev,2004,15:353-366.
[95]Jumper MD,Nishioka Y,Davis LS,Lipsky PE,Meek K.Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands.J Immunol,1995,155:2369-2378.
[96]Cerutti A,Schaffer A,Shah S,Zan H,Liou HC,Goodwin RG,et al.CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells.Immunity,1998,9:247-256.
[97]Cerutti A,Kim EC,Shah S,Schattner EJ,Zan H,Schaffer A,et al.Dysregulation of CD30+T cells by leukemia impairs isotype switching in normal B cells.[Erratum appears in Nat Immunol,2001, 2(4):368].NatImmunol,2001,2:150-156.
[98]Amakawa R,Hakem A,Kundig TM et al.Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice.Cell,1996,84:551-562.
[99]Kishimoto H,Sprent J.Several different cell surface molecules control negative selection of medullary thymocytes.J Exp Med,1999;190:65-73.
[100]De Young AL,Duramad 0,Winoto A.The TNF receptor family member CD30 is not essential for negative selection.J Immunol,2000,165:6170-6173.
[101]Flo'rido M,Borges M,Yagita H,Appelberg R.Contribution of CD30/CD153 but not of CD27/CD70,CD134/OX40L,or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.J Leukoc Biol,2004,76:1039-1046.
[102]Kurts C,Carbone FR,Krummel MF,Koch KM,Miller JF,Heath WR.Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.[Erratum appears in Nature,2000,407:413].Nature,1999,398:341-344.
[103]Heath WR,Kurts C,Caminschi I,Carbone FR,Miller JF.CD30 prevents T-cell responses to non-lymphoid tissues.Immunol Rev,1999,169:23-29.
[104]Kurts C,Carbone FR,Krummel MF,Koch KM,Miller JFAP,Heath WR.Correction:signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.Nature,2000,407:413.
[105]Gaspal FM,Kim MY,McConnell FM,Raykundalia C,Bekiaris V,Lane PJ.Mice deficient in OX40 and CD30 signals lack memory antibody responsesbecause of deficient CD4 T cell memory.J Immunol,2005,l 74:3891-3896.
[106]Blazar BR,Levy RB,Mak TW,et al.CD30/CD30 ligand(CD153) interaction regulates CD4+T cell-mediated graft-versus-host disease.J Immunol,2004,173:2933-2941.
[107]Podack ER,Strbo N,Sotosec V,Muta H.CD30-governor of memory T cells? Ann NY Acad Sci,2002,975:101-113.
[108]Susal C,Pelzl S,Dohler B,Opelz G.Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30.J Am Soc Nephrol,2002,13(6):1650-1656.
[109]Pelzl S,Opelz G,Daniel V,Wiesel M,Susal C.Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection.Transplantation,2003,75(3):421-423.
[110]Dong W,Shunliang Y,Weizhen W,Qinghua W,Zhangxin ZJianming T,He W.Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30.Transpl Immuno,l 2006,16(1):41.
[111]Susal C,Pelzl S,Simon T,et al.Advances in pre and posttransplant immunologic testing in kidney transplantation.Transplant Proc,2004,36:29-34.
[112]Pelzl S,Opelz G,WieselM,et al.Soluble CD30 as a predictor of kidney graft outcome.Transplantation,2002,73:3-6.
[113]Susal C,Pelzl S.Strang human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble cd30.Transplantation,2003576(8):1231-1232.
[114]Barth S,Huhn M.Ki-4(scFv)-ETA',a new recombinant anti-CD30immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.Blood,2000,95(12):3909-3914.
[115]Schuurman HJ,Cheng J,Lam T.Pathology of xenograft rejectionra commentary.Xenotransplantation,2003,10:293-299.
[116]PascualM,Vallhonrat H,Cosimi AB,et al.The clinical usefulness of the renal allograft biopsy in the cyclosporine era:a p rospective study.Transplantation,1999,67:737-741.
[117]Susal C,Pelzl S,Opelz G.High pretransp lant serum sCD30 content as a possible explanation for the high rejection rate in young kidney graft recipients.Pediatr Transplant,2003,7:48-49.
[118]Nakao K,Nagake Y,Okamoto A,et al.Serum levels of soluble CD26 and CD30 inpatients onhemodialysis.Nephron,2002,91:215-221.